Fate Therapeutics (NASDAQ: FATE) CFO receives RSU and stock option awards

Rhea-AI Filing Summary

Fate Therapeutics Chief Financial Officer Adawi Kamal reported new equity awards, including restricted stock units and stock options. On January 15, 2026, Kamal received 25,000 restricted stock units that vest in four equal installments on January 8 of each year from 2027 through 2030, subject to continued service. Each unit represents the right to receive one share of common stock upon settlement.

Kamal was also granted stock options for 75,000 shares of common stock at an exercise price of $1.05 per share. These options vest in 36 equal monthly installments following January 1, 2026, becoming fully vested and exercisable on January 1, 2029, if service continues. After these grants, Kamal beneficially owned 100,000 shares of common stock directly and held 75,000 stock options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Adawi Kamal

(Last) (First) (Middle)

C/O FATE THERAPEUTICS, INC.

12278 SCRIPPS SUMMIT DRIVE

(Street)

SAN DIEGO CA 92131

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
FATE THERAPEUTICS INC [ FATE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/15/2026		A(1)		25,000	A	$0.00	100,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.05	01/15/2026		A		75,000		(2)	01/14/2036	Common Stock	75,000	$0.00	75,000	D

Explanation of Responses:

1. Award of restricted stock units ("RSUs") that vest with respect to 1/4th of the RSUs on each of January 8, 2027, January 8, 2028, January 8, 2029 and January 8, 2030, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement.

2. The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2026, such that all of the shares shall be fully vested and exercisable on January 1, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.

	/s/ Cindy Tahl, as Attorney-in-Fact	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Fate Therapeutics (FATE) report for its CFO?

Fate Therapeutics reported that its Chief Financial Officer, Adawi Kamal, received equity awards consisting of 25,000 restricted stock units and stock options for 75,000 shares on January 15, 2026.

How do the new RSUs for Fate Therapeutics (FATE) CFO vest?

The 25,000 RSUs awarded to the Fate Therapeutics CFO vest in four equal installments, with 1/4 vesting on each of January 8, 2027, 2028, 2029 and 2030, subject to continued service.

What are the key terms of the Fate Therapeutics (FATE) CFO stock options?

The CFO received stock options for 75,000 shares of common stock with an exercise price of $1.05 per share. The options vest in 36 equal monthly installments following January 1, 2026, and are fully vested and exercisable on January 1, 2029, if service continues.

How many Fate Therapeutics (FATE) shares does the CFO own after these transactions?

After the reported transactions, the CFO beneficially owned 100,000 shares of common stock directly and held 75,000 stock options.

Were the Fate Therapeutics (FATE) CFO equity awards purchases for cash?

No. The filing shows the 25,000 RSUs and 75,000 stock options were recorded at a transaction price of $0.00, indicating they were granted as compensation rather than purchased.

Is the Fate Therapeutics (FATE) CFO Form 4 filed individually or jointly?

The Form 4 was filed by one reporting person, the CFO Adawi Kamal, and reflects direct ownership of the reported securities.